Chemical Biology and Drug Design p. 464 - 472 (2017)
Update date:2022-08-11
Topics:
Pereira, Glaécia A. N.
Souza, Gisele C.
Santos, Lourivaldo S.
Barata, Lauro E. S.
Meneses, Carla C. F.
Krettli, Antoniana U.
Daniel-Ribeiro, Cláudio Tadeu
Alves, Cláudio Nahum
The absence of effective vaccines against malaria and the difficulties associated with controlling mosquito vectors have left chemotherapy as the primary control measure against malaria. However, the emergence and spread of parasite resistance to conventional antimalarial drugs result in a worrisome scenario making the search for new drugs a priority. In the present study, the activities of nine neolignan derivatives were evaluated as follows: (i) against blood forms of chloroquine-resistant Plasmodium falciparum (clone W2), using the tritiated hypoxanthine incorporation and anti-HRPII assays; (ii) for cytotoxic activity against cultured human hepatoma cells (HepG2); and (iii) for intermolecular interaction with the P. falciparum cysteine protease of falcipain-2 (F2) by molecular docking. The neolignan derivatives 9 and 10 showed activity against the blood form of the chloroquine-resistant P. falciparum clone W2 and were not cytotoxic against cultured human hepatoma cells. A molecular docking study of these two neolignans with FP2 revealed several intermolecular interactions that should guide the design of future analogs.
View MoreContact:+86-25-8776 0031
Address:3-2001 Jiaye Int'l Town, 158 Lushan Road,Nanjing, 210019, China
Shanghai Synmedia Chemical Co., Ltd
Contact:+86-21-38681880
Address:6th Floor, 11A Building, No.528 Ruiqing Road, Heqing town, Pudong new district, Shanghai China
Changsha Goomoo Chemical Technology Co.Ltd
Contact:+86-731-82197655
Address:No.649,Chezhan Rd.(N),Changsha,Hunan,China
Luoyang Aoda chemical Co.,Ltd.
Contact:+86-379-67518785 67516588
Address:MiaoWan industry district,YanShi City,Henan,China
Contact:+86-511-88790000
Address:338 North Yushan Rd, Zhenjiang, Jiangsu 212016
Doi:10.1016/S0022-328X(00)93536-8
(1978)Doi:10.1016/S0040-4039(01)80206-9
(1984)Doi:10.1002/ejic.201700548
(2017)Doi:10.1016/j.jallcom.2018.04.274
(2018)Doi:10.1021/acs.joc.6b01072
(2016)Doi:10.1007/s11164-016-2579-7
(2016)